BioSpace News Archive

Carrum Health, a value-based Centers of Excellence healthcare solution changing how we pay for and deliver cancer and surgical care, and Texas Oncology, one of the largest community-based oncology practices in the U.S., today announced a new collaboration to provide high-quality, cost-effective breast cancer care to patients.

CLS Health proudly welcomes Megan Owen as the new CEO, effective immediately. With a distinguished background, including her role as a COO of Bay Area Hospital and Houston Eye Associates, Megan’s appointment marks a transformative moment in Houston healthcare.

RefleXion Medical, a therapeutic oncology company, today announced the initial closing of a $105M equity raise, led by The Rise Fund, TPG’s multi-sector global impact investing strategy.

MAIA Biotechnology, Inc., a clinical-stage biopharmaceutical company developing telomere-targeting immunotherapies for cancer, announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,424,243 of its shares of common stock at a purchase price of $1.65 per share in a registered direct offering.

Zymo Research announced today that the U.S. Food and Drug Administration (FDA) has cleared its DNA/RNA Shield™ SafeCollect™ Saliva Collection Kit as a Class II medical device for microbial nucleic acid storage and stabilization.

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a manuscript titled “LAIR-1 Agonism as a Therapy for Acute Myeloid Leukemia” in the Journal of Clinical Investigation.

Today, the U.S. Food and Drug Administration granted marketing authorization to LetsGetChecked for the Simple 2 Test.

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the third quarter and the first nine months of 2023.

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced plans to present at the upcoming 35th Annual Piper Sandler Healthcare Conference in New York.

Noetik Launches “Perturb-map” In Vivo Functional Genomics Platform and Adds Precision Immunology Leader Brian Brown, Ph.D. to Scientific Advisory Board.